Spots Global Cancer Trial Database for A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment
Official Title: A Phase 1/2a Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab Administered in Combination With Ipilimumab or Ipilimumab Alone in Participants With Unresectable or Metastatic Melanoma Who Have Progressed on Anti-PD-1 Therapy
Study ID: NCT03978611
Conditions
Study Description
Brief Summary: The primary purpose of this study is to characterize the safety, tolerability, and dose-limiting toxicities (DLTs) of relatlimab in combination with ipilimumab.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Local Institution - 0023, Tucson, Arizona, United States
Local Institution - 0002, Los Angeles, California, United States
Local Institution - 0005, Los Angeles, California, United States
Local Institution - 0001, Santa Monica, California, United States
Local Institution - 0015, Miami, Florida, United States
Local Institution - 0004, Chicago, Illinois, United States
Local Institution - 0003, Ann Arbor, Michigan, United States
Local Institution - 0008, Morristown, New Jersey, United States
Local Institution - 0018, Bruxelles, Brussels, Belgium
Local Institution - 0017, Antwerpen, , Belgium
Local Institution - 0016, Brussels, , Belgium
Local Institution - 0038, Bruxelles, , Belgium
Local Institution - 0044, Ottawa, Ontario, Canada
Local Institution - 0037, Erlangen, , Germany
Local Institution - 0034, Essen, , Germany
Local Institution - 0036, Gera, , Germany
Local Institution - 0035, Hannover, , Germany
Local Institution - 0033, Heidelberg, , Germany
Local Institution - 0032, Lübeck, , Germany
Local Institution - 0040, Nuremberg, , Germany
Local Institution - 0026, Barcelona, , Spain
Local Institution - 0030, Cordoba, , Spain
Local Institution - 0027, Hospitalet de Llobregat - Barcelona, , Spain
Local Institution - 0029, Madrid, , Spain
Local Institution - 0031, San Sebastian, , Spain
Local Institution - 0028, Valencia, , Spain
Contact Details
Name: Bristol-Myers Squibb
Affiliation: Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
